If you or someone you know, is over 18 years of age and are interested in any of our current clinical trials listed, you may contact us for more information to see if you qualify. If eligible, most trials will cover the cost of trial-related expenses and/or stipend. Email research@ncdhp.wpenginepowered.com your contact information and a study coordinator will contact you.
Currently Enrolling Studies – February 2026
BIO89-100-132: A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGOZAFERMIN IN SUBJECTS WITH COMPENSATED CIRRHOSIS DUE TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) **FIBROBLAST GROWTH FACTOR ANALOG **WEEKLY SUBQ INJECTION
( 1 ) REVAMP – M25-540: A Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who are Naïve to Targeted Therapies ** 1 year of therapy with risankizumab or vedolizumab **
( 2 ) EXIGEM – VEDO-4054: AN OPEN-LABEL, PHASE 4, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE INDUCTION OF RESPONSE AND REMISSION OF VEDOLIZUMAB DUAL TARGETED THERAPY WITH TOFACITININB IN ADULT PATEINTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS ** STANDARD Q8WK VEDOLIZUMAB INFUSIONS WITH 8 WEEKS OF TOFACITINIB DURING INDUCTION ** SOON EXPANDING TO PATIENTS NAÏVE TO BIOLOGICS **
ABBVIE- A PHASE 2A MULTICENTER, RANDOMIZED, PLATFORM STUDY OF TARGETED THERAPIES FOR THE TREATMENT OF ADULT SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE **BIOLOGIC EXPERIENCED ONLY** NO PLACEBO ARMS** NOVEL BIOLOGIC +/- SKYRIZI** LONG TERM EXTENSION W/ SKYRIZI**
AMETRINE-1 – GA45329: A PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREAT-THROUGH STUDY TO ASSESS THE EFFICACY AND SAFETY OF INDUCTION AND MAINTENANCE THERAPY WITH RO7790121 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS – PI: HARLAN – CONTACT: ANN JONES X3209 **BIOLOGIC NAIVE OR EXPERIENCED** TL1A ANTAGONIST** INCLUDES OPEN-LABEL CROSSOVER AND EXTENSION**
BIO89-100-132: A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGOZAFERMIN IN SUBJECTS WITH COMPENSATED CIRRHOSIS DUE TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) – PI: HARLAN – CONTACT: ANN JONES X3209 **FIBROBLAST GROWTH FACTOR ANALOG **WEEKLY SUBQ INJECTION
For Office or Procedure Appointments
New Patients
Step 1: Ask your primary care provider to send us a referral.
Step 2: Once we receive it, our scheduling team will contact you and send you a secure patient portal link
Current Patients
Log in to your Patient Portal to schedule online using your username and password.
Need help? Call your location:
